Pfizer Inc. is solidifying its position in the oncology market through a $43 billion acquisition of Seagen, known for its innovative antibody–drug conjugates. The FDA's recent grant of Priority Review for the PADCEV and Keytruda combination therapy for muscle-invasive bladder cancer further enhances Pfizer's portfolio, indicating potential approval that could significantly improve treatment outcomes. However, the company faces mixed analyst opinions and a stock decline in the face of market pressures, highlighting the challenges alongside its strategic advancements.
“$PFE $ALPMY FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility”
“CICC initiated coverage of Pfizer Inc. (NYSE:PFE) with an Outperform rating on April 16, setting a price target of $33.”
“Pfizer Inc. (NYSE:PFE) announced on March 23 topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405.”
“Pfizer Inc. (NYSE:PFE) further stated that the overall results bolster confidence in the vaccine candidate and that the company is planning submissions to regulatory authorities.”
“Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets, and is also involved in developing immunotherapies that help the immune system to recognise and attack cancer cells.”
“Astellas Pharma Inc. and Pfizer Inc. on Monday said the U.S. Food and Drug Administration has granted Priority Review for a supplemental Biologics License Application for perioperative PADCEV in combination with Keytruda as a treatment for patients with Muscle-Invasive Bladder Cancer (MIBC).”
“The current filing seeks to expand the indication to include patients regardless of cisplatin eligibility.”
“The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026.”
“Global drugmaker Pfizer and biotech firm Amgen, each valued at over HK$1T ($153B), are among 22 strategic enterprises planning to open or expand offices in Hong Kong, the South China Morning Post reported.”
“The U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental Biologics License Application (sBLA) for perioperative PADCEV™ in combination with pembrolizumab as treatment for patients with muscle-invasive bladder cancer (MIBC). The FDA grants Priority Review to medicines that may offer significant advances in treatment or may provide a treatment where limited therapy options exist.”
“If approved, perioperative PADCEV plus pembrolizumab could meaningfully change that experience, potentially helping patients reduce the risk of recurrence and live longer, regardless of whether they are eligible for cisplatin.”
“Results from the EV-304 trial showed a 47% reduction in the risk of tumor recurrence, progression or death and a 35% reduced risk of death for perioperative enfortumab vedotin in combination with pembrolizumab compared to standard of care.”
.svg&width=160)
